Cabergoline is a small-molecule research product rather than a peptide.
Also known as cabergoline
Research shortlist · Sep 12, 2026
No exact product basis had a qualifying vendor in the Sep 12, 2026 research snapshot.
Vendor records are available below, but the Sep 12, 2026 research snapshot did not support a same-product shortlist.
What it is
Cabergoline is an N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. It has a role as an antineoplastic agent, an antiparkinson drug and a dopamine agonist. The listed molecular formula is C26H37N5O2. PepGrades separately preserves the catalog category because a chemical identity record does not establish a use, outcome, or product quality.
This label describes the available research record, not whether the compound is safe or effective for an individual.
Research context
5 registered studies were found under this name in the current review. Each study still needs to be checked for the exact compound identity, population, endpoints, and results.
Search indexed research for this compound ↗Market context
Cabergoline is commonly sold or discussed for a range of compound-specific research goals. That describes market demand, not proof that the compound is safe or effective.
Market demand and online discussion do not establish product quality, safety, or effectiveness.Same format. Same amount.
0 of 0 formats had a qualifying research shortlist on Sep 12, 2026. Vendor counts below reflect the available price observations.
Vendor profiles and catalog information are still available below.
Vendor directory
Grades describe the vendor record overall. They are not a test result for every product.
| Vendor | Grade | Compared offers | In stock when checked | Lowest effective package | Profile |
|---|---|---|---|---|---|
| Peptides For SaleNot enough information to grade | Not enough information to grade | Not available | Not available | Not availableNo market observation | View → |
Sources and review
Last editorial review: Aug 30, 2026. Sources support the compound guide only and do not affect vendor grades.